BioStem Technologies, Inc. BSEM
BioStem Technologies, Inc. (Nasdaq: BSEM) is a life-science company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CLARIX family (cryopreserved amniotic membrane/umbilical cord allografts) | Surgical applications | biologic-other | NA_NON_THERAPEUTIC |
| NEOX family (cryopreserved amniotic membrane/umbilical cord allografts) | Chronic wound care; hospital wound management | biologic-other | NA_NON_THERAPEUTIC |
| VENDAJE family (dry amniotic membrane allografts) | Soft tissue wound coverings | biologic-other | NA_NON_THERAPEUTIC |
| Catalyze (510(k)-cleared particulate wound device, commercial rights being acquired) | Wound coverage and moist wound environment | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.